PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Timeless Wealth

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

TimelessWealth Publishes Investment Report on Prospective Pharmaceutical Company Telik, Inc. - Investment Report on Prospective Pharmaceutical Company: Telik, Inc. (NASDAQ: TELK). Overview of Market Trend in Healthcare Sector, comparison with other Drug Manufacturers’ price performance, fundamental and brief chart analysis - TimelessWealth.net
TimelessWealth Publishes Investment Report on Prospective Pharmaceutical Company Telik, Inc.

 

NewswireToday - /newswire/ - Richmond Hill, Ontario, Canada, 2010/04/05 - Investment Report on Prospective Pharmaceutical Company: Telik, Inc. (NASDAQ: TELK). Overview of Market Trend in Healthcare Sector, comparison with other Drug Manufacturers’ price performance, fundamental and brief chart analysis - TimelessWealth.net.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

While Biotech Stocks have traditionally provided returns in leaps and bounds, Cancer Drug Manufacturers have recreated a 'Cinderella' story turning modest investments into retirement funds. Just three months ago, Somaxon Pharmaceuticals was trading for less than $1.00/share, capitalized under $30M. Since then it has boasted a 759% jump in price, leaving speculators hungry for other opportunities and another shot at financial bliss.

In fact, as we put together this report for our Newsletter Subscribers, it took our Staff less than 10 minutes to track down several Cancer Drug Manufacturers that have soared in the marketplace this year.

Nevertheless, the question remains: How do we capitalize in the Market knowing what we know?

All seven stocks listed (above) were small, Cancer Drug Manufacturers trading under Wall Street and Main Street's radar. That tells us the next Biotech Mover is a Micro Cap Company that trades relatively small or 'quiet' volume...at least at this point in time.

Enter Telik Inc. (NASDAQ: TELK), a clinical stage drug development company, focused on discovering and developing small molecule drugs to treat cancer. While analysts will bore investors with intricate detail, we will keep our report concise and give you three reasons why Telik, Inc. (NASDAQ: TELK) is an exciting Biotech Play:

(1) -TIMING- "The key is to find undervalued cancer drug makers that pose nominal downside risk but retain potential for serious growth", writes SeekingAlpha columnist Justin M. Hall, in an article on the hot trend among 'Cancer Drug Makers'. Telik, Inc. is trading at a 38% discount to its 52-week high ($1.40), a mark that could provide investors with a 61% return from the recent price per share ($0.87). Telik continues to be encouraged by long-term supporting levels just below as the price looks to break resistance for the fifth time in 10 months.

(2) -RISK MANAGEMENT- One of the greater risks involving an investment in development-stage biotech companies is the necessity for Companies to raise capital to fund operations. That hurts the share price, and consequently, shareholders. Reiterating Telik's 2010 Guidance, "The Company’s cash utilization for the full year 2010 is expected to be in the range of $18.0 million to $20.0 million". With roughly $40M in cash, the company is well positioned to cover expenses without having to resort to stock offerings to raise capital. Investors have a high chance of evading this risk in Telik, Inc.

(3) -POSITIONING- There is something oddly convincing about a Company where 56% ownership belongs to Institutional Investors. When the likes of MORGAN STANLEY, EASTBOURNE CAPITAL MANAGEMENT LLC, and OPPENHEIMER FUNDS, INC. have a combined vested interest of $19M in Telik, Inc. that tells retail investors there is something going on 'behind the scenes'. Whether that ‘something' is a FDA approval of a Drug, a lucrative buy-out or 'takeover', only time will reveal. Meanwhile, 'free trading' shares less institutional holdings, results in a float under 23M shares. That attracts speculators.

Telik's Drug Pipeline includes development candidate TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Timeless Wealth

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Brokerage/Trading articles,
CATCH Visitors via Your Competitors Announcements!


TimelessWealth Publishes Investment Report on Prospective Pharmaceutical Company Telik, Inc.

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Edward Stevenson - TimelessWealth.net 
416-877-6622 staff[.]timelesswealth.net
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Timeless Wealth securities in any jurisdiction including any other companies listed or named in this release.

Brokerage/Trading via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Timeless Wealth / Company Profile


Read Brokerage/Trading Most Recent Related Newswires:

SRMEX's Vice Chairman Eikichi Hirano About the Gradual Expansion of Capital Market
Xtrade Wins Best Broker in the Middle East Award
Russian Foreign Trade Reports on Russian Trade with North American Countries Q1 2016
DarkMaindFX Introduces the Beta Version of its Economic Indicator Services
Hermes International Expo to Celebrate 25th Anniversary in Delaware County
GoldSilver Central Approved As Singapore Bullion Market Association Member
OANDA Acquires Tradestation Forex Accounts
[TYPO FOUND BY SYSTEM] Beeline Broking Ltd Launches 'Tailor Made Brokerage Plan'
Signals365.com Announces Key Features - Makes it the Best Binary Options Signals Service
Binary Options Signals from Signals365.com Helps Traders to Get Higher Win-Rate
/RC/ Van Ecker Couder Associates Announce Expansion Program
/RC/ Voth Nixon Group Bolsters Deferred Income Annuity
Grant Becker Associates Chalks Up Another Successful Year of CSR Activities
Evanson Asset Management Dividend Stocks to Safeguard An All-weather Portfolio
AKFinancials Announces its 2015 Forex Course Schedule

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)